Cabaletta Bio's Cell Therapy Shows Encouraging Safety Profile In Autoimmune Skin Disorder

  • Cabaletta Bio Inc CABA has announced 28-day data from the second dose cohort from the DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus vulgaris (mPV).
  • Related: Cabaletta Announced Favorable Safety Profile From First Cohort Of Phase 1 Study.
  • Patients received 100 million DSG3-CAART cells in the second cohort, a five-fold higher dose than the initial cohort.
  • No clinically relevant adverse events or dose-limiting toxicities were observed. 
  • Similar to the first cohort, the safety profile was observed in the presence of circulating anti-DSG3 antibodies. 
  • The DesCAARTes trial has initiated dosing of patients in the third cohort at a treatment dose of 500 million DSG3-CAART cells. 
  • Cabaletta expects to announce top-line data on biologic activity from the first two cohorts and safety data from the 500 million dose cohort in Q4 of 2021. 
  • Absent DLTs in the third cohort, a fourth dose cohort using 2.5 billion cells will also initiate dosing in 2021. 
  • Price Action: CABA shares are up 1.21% at $7.50 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralautoimmune diseasesBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!